Skip to content
TrialScanner

NCT04480710

A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

Phase 2CompletedHEPALead

Registry record

Lead sponsor
Hepion Pharmaceuticals, Inc.
Conditions
NASH - Nonalcoholic Steatohepatitis; Fibrosis, Liver; NAFLD - Nonalcoholic Fatty Liver Disease
Primary completion
Jun 29, 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04480710 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04480710: A Study of CRV431 Dosed Once... | TrialScanner